Modulation of cisplatin chronotoxicity related to reduced glutathione in mice

被引:15
作者
Boughattas, NA
Li, XM
Filipski, J
Lemaigre, G
Filipski, E
Bouzouita, K
Belhadj, O
Levi, F
机构
[1] HOP PAUL BROUSSE,LAB RYTHMES BIOL & CHRONOTHERAPEUT,F-94800 VILLEJUIF,FRANCE
[2] UNIV PARIS 07,INST JACQUES MONOD,MOLEC BIOL LAB,F-75251 PARIS,FRANCE
[3] FAC SCI,BIOCHIM LAB,TUNIS 1002,TUNISIA
[4] HOP ANTOINE BECLERE,ANAT PATHOL LAB,CLAMART 92,FRANCE
来源
HUMAN & EXPERIMENTAL TOXICOLOGY | 1996年 / 15卷 / 07期
关键词
circadian rhythm; cisplatin; reduced glutathione; buthionine sulfoximine; toxicity;
D O I
10.1177/096032719601500703
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Intracellular reduced glutathione (GSH) concentrations were measured according to the tissue sampling-time along the 24 h scale in male B6D2F1 mice. A significant circadian rhythm in GSH content was statistically validated in liver, jejunum, colon and bone-marrow (P less than or equal to 0.02) but not in kidney. Tissue GSH concentration increased in the dark-activity span and decreased in the light-rest span of mice. The minimum and maximum of tissue GSH content corresponded respectively to the maximum and minimum of cisplatin (CDDP) toxicity. The role of GSH rhythms with regard to CDDP toxicity was investigated, using a specific inhibitor of GSH biosynthesis, buthionine sulfoximine (BSO). Its effects were assessed on both tissue GSH levels and CDDP toxicity at three circadian times. BSO resulted in a 10-fold decrease of the 24 h-mean GSH in kidney. However a moderate GSH decrease characterized liver (-23%) and jejunum (-30%). BSO pretreatment largely enhanced CDDP toxicity which varied according to a circadian rhythm. Although BSO partly and/or totally abolished the tissue GSH rhythms, it did not modify those in CDDP toxicity. We conclude that GSH have an important influence on CDDP toxicity but not in the circadian mechanism of such platinum chronotoxicity.
引用
收藏
页码:563 / 572
页数:10
相关论文
共 40 条
[1]  
BELANGER PM, 1991, DRUG METAB DISPOS, V19, P241
[2]  
Belanger PM., 1987, ANN REV CHRONOPHARMA, V4, P1
[3]  
BELANGER PM, 1988, ANN REV CHRONOPHARMA, V4, P215
[4]  
BOOR PJ, 1979, RES COMMUN CHEM PATH, V24, P27
[5]  
BOUGHATTAS NA, 1989, CANCER RES, V49, P3362
[6]   CIRCADIAN TIME-DEPENDENCE OF MURINE TOLERANCE FOR CARBOPLATIN [J].
BOUGHATTAS, NA ;
LEVI, F ;
HECQUET, B ;
LEMAIGRE, G ;
ROULON, A ;
FOURNIER, C ;
REINBERG, A .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1988, 96 (02) :233-247
[7]   COMPARATIVE PHARMACOKINETICS OF OXALIPLATIN (L-OHP) AND CARBOPLATIN (CBDCA) IN MICE WITH REFERENCE TO CIRCADIAN DOSING TIME [J].
BOUGHATTAS, NA ;
HECQUET, B ;
FOURNIER, C ;
BRUGUEROLLE, B ;
TRABELSI, H ;
BOUZOUITA, K ;
OMRANE, B ;
LEVI, F .
BIOPHARMACEUTICS & DRUG DISPOSITION, 1994, 15 (09) :761-773
[8]  
BOUGHATTAS NA, 1990, J PHARMACOL EXP THER, V255, P672
[9]   PHASE-I TRIAL OF 5-DAY CONTINUOUS VENOUS INFUSION OF OXALIPLATIN AT CIRCADIAN RHYTHM-MODULATED RATE COMPARED WITH CONSTANT RATE [J].
CAUSSANEL, JP ;
LEVI, F ;
BRIENZA, S ;
MISSET, JL ;
ITZHAKI, M ;
ADAM, R ;
MILANO, G ;
HECQUET, B ;
MATHE, G .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (12) :1046-1050
[10]  
DREWINKO B, 1973, CANCER RES, V33, P3091